TNAX 101A
Alternative Names: IBM-1001; TNAX-101ALatest Information Update: 05 Mar 2024
At a glance
- Originator TNAX Biopharma Corporation
- Developer IMIDomics; TNAX Biopharma Corporation
- Class Anti-inflammatories; Antifibrotics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD226 antigen inhibitors; Natural killer T cell inhibitors; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Crohn's disease; Systemic lupus erythematosus
Most Recent Events
- 05 Mar 2024 TNAX Biopharma plan to initiate first in human trial and subsequent studies in inflammatory bowel disease (TNAX Biopharma pipeline, March 2024)
- 08 Sep 2023 Efficacy and adverse events data from a preclinial trial in Systemic lupus erythematosus and Crohn's disease released by TNAX Biopharma (TNAX Biopharma pipeline, September 2023)
- 08 Sep 2023 Pharmacodynamics and adverse event data from a preclinical trial in Systemic lupus erythromatosus ans Crohn's diseases released by TNAX Biopharma (TNAX Biopharma pipeline, September 2023)